Hepatic Dysfunction Associated with Troglitazone

Abstract

Troglitazone is a thiazolidine 2,4-dione derivative that represents a novel class of oral drugs for the treatment of diabetes. In clinical trials, including two published in this issue of the Journal, ^1,2 troglitazone has increased insulin action, enhanced oral glucose utilization, and improved dyslipidemia in patients with type II diabetes. Since its introduction in March 1997, more than 600,000 patients have received troglitazone in the United States and an additional 200,000 have received the drug in Japan.